BOONE CAPITAL MANAGEMENT LLC — 13F Holdings & Portfolio
CIK 1882053 · latest 13F-HR filed 2026-08-14
BOONE CAPITAL MANAGEMENT LLC manages $427.5M in 13F-reported U.S. long-equity assets across 16 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are TFX (11.49%), MIRM (11.38%), CI (10.27%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 7 new positions, exited 4, added to 9, and trimmed 0.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
SUITE 1625
ATLANTA, GA 30361
$427.5M
Long-equity book
16
Distinct positions
2026-06-30
Filed 2026-08-14
+7 / −4 / ↑9 / ↓0
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- TELEFLEX INCORPORATED$15.8M +47.3%
- UNITEDHEALTH GROUP INC$15.4M +71.9%
- MIRUM PHARMACEUTICALS INC$9.7M +25.0%
- BRIDGEBIO PHARMA INC$8.3M +48.9%
- THE CIGNA GROUP$7.2M +19.7%
New Positions
- VESTIS CORPORATION$27.6M
- PENNANT GROUP INC$19.1M
- MONTE ROSA THERAPEUTICS INC$14.9M
- TANGO THERAPEUTICS INC$14.2M
- KYMERA THERAPEUTICS INC$13.0M
Exited Positions
- MEDTRONIC PLC$34.5M
- ASTRAZENECA PLC$21.7M
- AVANOS MED INC$16.6M
- TENAX THERAPEUTICS INC$3.2M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | TELEFLEX INCORPORATED | TFX | 879369106 | $49.1M | 11.49% | 387,388 | SH |
| 2 | MIRUM PHARMACEUTICALS INC | MIRM | 604749101 | $48.7M | 11.38% | 415,641 | SH |
| 3 | THE CIGNA GROUP | CI | 125523100 | $43.9M | 10.27% | 159,290 | SH |
| 4 | IONIS PHARMACEUTICALS INC | IONS | 462222100 | $41.2M | 9.64% | 519,977 | SH |
| 5 | UNITEDHEALTH GROUP INC | UNH | 91324P102 | $36.9M | 8.62% | 88,687 | SH |
| 6 | BIOMARIN PHARMACEUTICAL INC | BMRN | 09061G101 | $33.4M | 7.81% | 583,219 | SH |
| 7 | GUARDIAN PHARMACY SVCS INC | GRDN | 40145W101 | $29.8M | 6.97% | 711,939 | SH |
| 8 | VESTIS CORPORATION | VSTS | 29430C102 | $27.6M | 6.45% | 1,900,140 | SH |
| 9 | BRIDGEBIO PHARMA INC | BBIO | 10806X102 | $25.3M | 5.92% | 339,720 | SH |
| 10 | PENNANT GROUP INC | PNTG | 70805E109 | $19.1M | 4.46% | 515,818 | SH |
| 11 | MONTE ROSA THERAPEUTICS INC | GLUE | 61225M102 | $14.9M | 3.48% | 615,287 | SH |
| 12 | KODIAK SCIENCES INC | KOD | 50015M109 | $14.7M | 3.44% | 378,010 | SH |
| 13 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $14.2M | 3.33% | 455,605 | SH |
| 14 | KYMERA THERAPEUTICS INC | KYMR | 501575104 | $13.0M | 3.04% | 113,173 | SH |
| 15 | CULLINAN THERAPEUTICS INC | CGEM | 230031106 | $12.8M | 3.00% | 704,442 | SH |
| 16 | ADLAI NORTYE LTD | ANL | 00704R109 | $3.0M | 0.70% | 258,390 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $427.5M | 16 | 0001214659-26-010362 |
| 2026-03-31 | 2026-05-15 | $326.4M | 13 | 0001214659-26-006448 |
| 2025-12-31 | 2026-02-17 | $318.6M | 15 | 0001214659-26-001960 |
| 2025-09-30 | 2025-11-14 | $305.0M | 16 | 0001214659-25-016617 |